Pallas Capital Advisors LLC Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Pallas Capital Advisors LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, Holdings Channel reports. The firm purchased 10,365 shares of the medical research company’s stock, valued at approximately $5,197,000.

Several other hedge funds also recently modified their holdings of the company. Deutsche Bank AG bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth $609,053,000. Perigon Wealth Management LLC acquired a new stake in shares of Thermo Fisher Scientific during the second quarter valued at about $13,385,000. Commerzbank Aktiengesellschaft FI bought a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $32,967,000. Trust Co. of Vermont acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $25,326,000. Finally, Principle Wealth Partners LLC bought a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $1,677,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total value of $15,300,000.00. Following the completion of the transaction, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock valued at $30,643,589 over the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.8%

Shares of NYSE TMO opened at $590.00 on Wednesday. The company’s 50 day moving average price is $533.64 and its 200-day moving average price is $508.36. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The company has a market capitalization of $218.15 billion, a P/E ratio of 31.74, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the company posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on TMO. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.